All reports
No Surprises Act (NSA)
Price transparency regulations
Transparency compliance
Industry analysis

Evaluating the HHS report on the No Surprises Act

Evaluating the HHS report on the No Surprises Act

Turquoise Health is tracking all components of the No Surprises Act (NSA), including the first annual report. This document focuses on a review of the report, analyzing stalled or broken processes within the NSA, and recommended pathways forward.

Download PDF

Related resources

Learn, listen, and watch the latest on price transparency.

View all
Turquoise's public comment on CMS-1834-P
Public comment

Turquoise's public comment on CMS-1834-P

Turquoise Health's public comment on CMS-1834-P supporting comprehensive hospital MRF standards, seeking clarification on new percentile fields, and providing recommendations on EDI 835 ERA transaction data utility. Read our full analysis.

2025 drug reimbursement trends report
Drug pricing data

2025 drug reimbursement trends report

Turquoise Health and ZS's 2025 drug reimbursement trends report analyzes millions of hospital and payer-reported drug rates across 17 products and 4 therapeutic areas revealing how payer-provider dynamics drive reimbursement from 3× to 10× ASP. Explore the data.

Turquoise's public comment on CMS hospital price transparency accuracy and completeness RFI
Public comment

Turquoise's public comment on CMS hospital price transparency accuracy and completeness RFI

Turquoise Health's full response to the CMS hospital price transparency accuracy & completeness RFI defining accuracy and completeness of MRF data and recommending how CMS should enforce meaningful compliance going forward. Read our full analysis.